Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Breast 1

Conditions

Breast Neoplasms 395Neoplasms 350Carcinoma, Non-Small-Cell Lung 313Prostatic Neoplasms 264Colorectal Neoplasms 236Lung Neoplasms 204Multiple Myeloma 163Pancreatic Neoplasms 147Ovarian Neoplasms 146Neoplasm Metastasis 141Leukemia, Myeloid, Acute 138Melanoma 118Squamous Cell Carcinoma of Head and Neck 100Carcinoma, Renal Cell 93Stomach Neoplasms 92Recurrence 92Lymphoma 91Lymphoma, Non-Hodgkin 89Endometrial Neoplasms 89Carcinoma, Hepatocellular 89Precursor Cell Lymphoblastic Leukemia-Lymphoma 87Glioblastoma 85Brain Neoplasms 84Head and Neck Neoplasms 77Glioma 76Uterine Cervical Neoplasms 75Urinary Bladder Neoplasms 72Sarcoma 70Leukemia, Lymphocytic, Chronic, B-Cell 70Hematologic Neoplasms 68

Interventions

exemestane 1Leuprolide 1Letrozole 1Goserelin 1Gonadotropin-Releasing Hormone 1Bupropion 1Aromatase Inhibitors 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sexual Dysfunctions, Psychological × 30 days × Clear all
NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

University of Illinois at Chicago

Phase 1/2 Not yet recruiting
100 enrolled
BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

Data powered by HemOnc (CC BY 4.0) Colophon âš¡